Many therapeutic monoclonal antibodies have been found to elicit an immune response to various degrees. Anti-drug antibodies (ADA) can diminish efficacy by neutralization or enhanced clearance of the therapeutics, and occasionally cause hypersensitivity reactions or other adverse events.
To the Editor:
Many therapeutic monoclonal antibodies have been found to elicit an immune response to various degrees. Anti-drug antibodies (ADA) can diminish efficacy by neutralization or enhanced clearance of the therapeutics, and occasionally cause hypersensitivity reactions or other adverse events. 1 Therapeutic antibodies are classified as chimeric, humanized or 'fully human', in order of increasing homology of the variable domains with human germ-line sequences, and thereby their expected decrease in immunogenicity.
Recently, our group investigated the antibody repertoire in patients with an immune response against any of four different anti-TNF therapeutic antibodies. 2, 3 For the human(ized) adalimumab, certolizumab and golimumab, >94% were found to bind the TNF binding site, demonstrating that these ADA are essentially all neutralizing. Strikingly, the antibody response to the chimeric infliximab, of which the entire variable domains are of mouse origin, was also >90% directed to the TNF binding site. These results prompted the question whether this restricted response is due to specific immunogenic properties of the anti-TNF binding site, or that the antigen binding site (or paratope) is an inherently immunodominant part of the antibody, irrespective of its target. If so, antidrug antibodies to any therapeutic antibody might be expected to be predominantly neutralizing.
To shed light on this question, we investigated the antibody response to natalizumab, a humanized antibody that differs in target (α4-integrin), subclass (IgG4) and patient group (relapsing-remitting multiple sclerosis, RRMS) from anti-TNF therapeutics. Natalizumab contains several non-human germline determinants outside of its paratope ( Figure 1A ) and can thus theoretically elicit a broad non-neutralizing antibody response. In this study, we examined the neutralizing capacity of the anti-natalizumab response of RRMS patients.
We therefore first developed human monoclonal anti-natalizumab antibodies. Variable domain sequences of in total three natalizumab specific peripheral blood B cells were obtained from two patients (Table E1 ). These sequences were recombinantly expressed in HEK293F cells, resulting in three human monoclonal anti-natalizumab antibodies. Analysis of the clones using ImMunoGeneTics/V-QUEry and STandardization (IMGT/VQuest) 4 revealed a distinct V(D)J gene usage for each clone. Using surface plasmon resonance (SPR), the affinity of anti-natalizumab 1.1 and 2.1 was found to be moderate, whereas anti-natalizumab 2.2 had a high affinity (1x10 -11 mol/L; Figure E1 , Table E2 ).
To investigate the natalizumab binding site for each clone relative to the others, the antibodies were tested in a competitive ELISA. In this assay, the binding of a labeled 98 clone was assessed in the presence of a competing non-labeled clone ( Figure 1B) . The results showed that the monoclonal antibodies all competed with each other for binding to natalizumab ( Figure 1C ), indicating that all three monoclonal antibodies bind to a restricted site on natalizumab.
We further examined whether the monoclonal antibodies could block the binding of natalizumab to its target α4-integrin. This was tested using fluorescently labeled natalizumab that binds α4-integrin expressed on Jurkat cells. Preincubation of natalizumab with any of the three monoclonal antibodies abrogated the binding of natalizumab to α4-integrin ( Figure 1D ,E). Similar results were found for the binding of exchanged (i.e. monovalent, see 'IgG4 half-molecule exchange' in Repository Text) natalizumab to α4-integrin ( Figure E2 ). This indicates that all three monoclonal antinatalizumab antibodies compete with α4-integrin for binding to natalizumab, and are thus all neutralizing.
Next, we investigated the neutralizing capacity of polyclonal anti-natalizumab antibodies from 15 ADA-positive patients. A competitive ELISA was set up in which α4-integrin blocks the paratope of natalizumab ( Figure 2A ). For all patients, the binding of ADA to natalizumab was reduced with increasing concentrations of α4-integrin ( Figure 2B ). With the highest amount of α4-integrin tested, the signal was reduced by at least 91% compared to the uninhibited signal ( Figure 2C ). This indicates that for all patients tested, at least 91% of all ADA to natalizumab are neutralizing.
We further analyzed which parts of natalizumab are targeted by the anti-natalizumab response using a similar competitive assay, but now using neutralizing, but less bulky, Fab fragments of monoclonal anti-natalizumab 2.2 to block the binding site of natalizumab ( Figure 2D ). Again, the binding of patient ADA to natalizumab could be reduced in a concentration-dependent manner, ultimately preventing at least 92% of ADA from binding natalizumab using this single monoclonal antibody ( Figure 2E ,F). This implies that the majority of ADA from RRMS patients binds determinants of natalizumab located in or in close proximity to the paratope.
The results from this present study on the anti-natalizumab response, in combination with our previous findings on the neutralizing capacity of ADA to anti-TNF therapeutics, 2, 3 indicates that the immune response preferentially targets the paratope of at least several classes of therapeutic antibodies. The antigen specificity of the drug seems irrelevant for this response. In addition, the non-human germline determinants outside of the paratope found in natalizumab, as well as those in the chimeric infliximab (and even in the other humanized and fully human anti-TNFs) apparently are less immunogenic. This observation is also consistent with the lack of immune response towards mismatched allotypes of therapeutic antibodies. 6 The paratope of therapeutic antibodies, but perhaps of any antibody, might be intrinsically more immunogenic than other determinants outside of the paratope. It is however unknown whether the paratope displays specific structural features that facilitates its potential role as epitope. For infliximab, attempts were made to more precisely locate immunogenic amino acid sequences using synthetic peptides. Homann et al. found reactivity of ADA-positive patients to four peptide sequences located in or in close proximity to the complementarity determining regions (CDRs), although two of these peptides were also recognized by healthy controls. 7 By contrast, a study by Kosmac et al. showed no reactivity to synthetic peptides nor to denatured infliximab Fab, suggesting that anti-infliximab antibodies target conformational rather that linear epitopes. 8 Our findings on the neutralizing capacity of ADA to natalizumab are in line with a study of Calabresi et al. 9 in which ADA to natalizumab were analyzed using an ELISA that measures all ADA and a cell-blocking assay that only measures neutralizing ADA. The strong correlation between the two assays suggested that most or all ADA to natalizumab were neutralizing.
In conclusion, this study shows that the majority of the polyclonal anti-natalizumab response in RRMS patients specifically targets the antigen binding site of natalizumab, and thereby extends the results previously obtained for anti-TNF antibodies. 2, 3 Although exceptions cannot be ruled out, these results suggest that the immune response towards antibody therapeutics may preferentially be directed towards the paratope of the drug, and will thus inherently neutralize the therapeutics. 
MATERIALS AND METHODS

Patients
For the development of human monoclonal anti-natalizumab antibodies, EDTA blood was collected from two ADA-positive RRMS patients. For the competitive assays, serum samples of 7 patients with anti-natalizumab antibodies were selected from a prospective observational cohort previously described by Vennegoor et al. 2 After obtaining informed consent, blood was taken from these patients. The study was approved by the ethics committee of the VU Medical Center, Amsterdam. In addition, anti-natalizumab antibody positive sera were obtained from our diagnostic department (n=8). Materials were used anonymously without any connection to clinical data. Anti-natalizumab positivity was measured using a previously described antigen binding test.
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Development of human monoclonal anti-natalizumab antibodies
Natalizumab specific B-cells were isolated essentially as described before, 4 with the modification that DAPI negative, anti-CD20-PerCP-Cy5.5 positive, anti-IgD-FITC negative (all from BD Biosciences) memory B-cells were selected, after which cells double positive for natalizumab F(ab) 2 -AF647 (Invitrogen, labeled according to the manufacturer's instructions) and biotinylated natalizumab F(ab) 2 combined with streptavidin-PE (BD Bioscience) were placed one cell per well in 96-well flat bottom plates. Determining the type of subclass and light chain of monoclonal anti-natalizumab antibodies, and production of the recombinant antibodies was done as described before.
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Natalizumab bridging ELISA B cell supernatants and recombinant monoclonal anti-natalizumab antibodies were tested for anti-natalizumab specificity using a bridging ELISA as described before, with slight adjustments. 4 In short, samples (diluted appropriately in PTG (PBS containing 0.2% gelatin (Merck, Germany) and 0.1% Tween-20) were added to a natalizumab coated plate (0.25 µg/ml in PBS), followed by detection with biotinylated natalizumab F(ab) 2 (50 ng/ml).
Generation of F(ab) 2 and Fab' and Fab fragments
F(ab') 2 and Fab' fragments were generated using pepsin, and subsequent reduction and alkylation with dithiothreitol and iodoacetamide respectively, essentially as described. 6 Fab fragments were generated by papain digestion as described, 7 with the exception that the enzyme : antibody ratio was 1:10.
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Surface plasmon resonance measurements
Surface plasmon resonance measurements were performed using a Biacore T200 instrument (GE Healthcare) at 25°C. Mouse anti-human IgG (MH16-1, Sanquin) was immobilized at a concentration of 5 µg/ml in 10 mM sodium acetate, pH 5.0, at a flow rate of 10 µl/min on a CM5 sensor chip using N-hydrosuccinimide/1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride (NHS/EDC). Anti-natalizumab monoclonal antibodies were dissolved at 5 µg/ml in PBS pH 7.4, containing 0.05% Tween-20 (PBS-T), and passed through the cells at 15 µl/min yielding ca. 100-300 response units (RU) of bound antibody. Subsequently, binding of natalizumab Fab' (0.125 -1.25 µg/ml) dissolved in PBS-T was measured at a flow rate of 15 µl/min. After each run, immobilized ligand was regenerated by removing bound analyte with 5 µl of 0.1 M phosphoric acid. Adsorptions obtained in the reference channel without bound anti-natalizumab antibody was subtracted from the adsorptions in the other cells. Association and dissociation kinetics were fitted using the models provided with the Biacore analysis software.
Competitive ELISA with mAbs as inhibitor
A 96-well flatbottom MaxiSorp plate was coated with 0.25 µg/ml natalizumab in PBS and incubated overnight. Plates were washed with PBS-T. Biotinylated anti-natalizumab was preincubated at 0.15 µg/ml in PTG together with unlabeled anti-natalizumab at a final concentration of 1 or 5 µg/ml and subsequently added to the plate. After 1 hour incubation, plates were washed and incubated for 25 minutes with streptavidin-poly HRP (horseradish peroxidase, Sanquin, The Netherlands) diluted in PTG, after which plates were washed again and developed using substrate solution. Samples were measured at 450nm and 540nm.
IgG4 half-molecule exchange
IgG4 antibodies have the property to exchange half-molecules (i.e. one heavy chain and its attached light chain) with other IgG4 molecules. This half-molecule exchange occurs under physiological conditions in patients and healthy people. Natalizumab is an IgG4 antibody and is able to exchange with autologous IgG4, thus becoming monovalent. 8 To create monovalent fluorescently-labeled natalizumab, natalizumab labeled with DyLight488 (natalizumab-AF488, Invitrogen, labeled according to the manufacturer's instructions) was incubated with a 100-fold excess of anti-adalimumab IgG4 in the presence of 1mM GSH (reduced glutathione) at 37°C as described previously. 3 After 24h the reaction was stopped by adding iodoacetamide to a concentration of 1mM. A bridging ELISA was used to check exchange of natalizumab: exchanged natalizumab is unable to form a bridge between coat and detection antibody.
